Haemonetics Positioned for Strong Growth: Buy Rating Justified Amidst Operational and Financial Optimism

Analyst Anthony Petrone of Mizuho Securities maintained a Buy rating on Haemonetics (HAE – Research Report), with a price target of $115.00.

Anthony Petrone has given his Buy rating due to a combination of factors surrounding Haemonetics’s financial and operational outlook. The clarity provided on the company’s fiscal year 2025 guidance has revealed a path towards a high-20s operating margin by fiscal year 2026, an indicator of strong financial health and performance. Despite the rolloff of the CSL contract, which was initially a concern, Haemonetics has demonstrated resilience with expected 8-12% organic growth in their non-PCS2 plasma business, and advancements in plasma technology and market share that could render these estimates conservative. Additionally, gross margin expansion is a major factor, with projections of 400-600 basis points improvement through FY26, primarily driven by a strategic shift in the hospital product mix.
Furthermore, the acquisition of OpSens and the growth of the VASCADE MVP product in the electrophysiology space are anticipated to contribute to the company’s revenue, nearly equating to that of the Plasma segment, but with higher margins. This is expected to be accretive to Haemonetics’s growth and help offset the decline from CSL’s contract termination. Despite the headwinds from the loss of CSL revenue, Haemonetics projects an impressive 12-20% adjusted EPS growth for FY25. These factors, combined with Haemonetics’s strong capital position and restructuring gains, provide a robust case for the company’s long-term growth potential and justify the Buy rating.

According to TipRanks, Petrone is a 4-star analyst with an average return of 6.0% and a 51.80% success rate. Petrone covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Staar Surgical, and Nevro Corp.

In another report released on May 10, Barrington also maintained a Buy rating on the stock with a $107.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Haemonetics (HAE) Company Description:

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other. Its products include surgical and diagnostic devices, blood and plasma center devices, blood center software, hospital software, and plasma center software. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA.